TEM Stock Jumps As Tempus AI Lifts Guidance And Expands Moat

Tempus AI Inc. stocks have been trading up by 9.89 percent after upbeat coverage highlighted its strong AI-driven healthcare potential.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Tempus AI (TEM) reported Q2 revenue modestly above consensus, raised full-year guidance to about $1.6B, expanded gross margin to 64%, and printed positive net income while still funding heavy R&D.
Shares of Tempus AI are trading well below prior 2025 highs even as guidance moves up and profitability improves, with analysts trimming targets after a period of sky-high expectations.
Tempus AI is acquiring Personalis, a precision oncology MRD specialist, for $16.25 per share, bolstering its oncology diagnostics footprint and long-term product pipeline.
A shareholder-rights firm is reviewing whether Tempus AI’s existing stake and ties to Personalis pressured PSNL holders into accepting an unfairly low deal price.
Tempus AI is framed as a major AI–healthcare platform, leveraging hundreds of petabytes of clinical and genomic data from tens of millions of patients as a core competitive moat.

Live Update At 12:34:02 EDT: On Thursday, August 20, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 9.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI (TEM) is finally putting numbers behind its AI story. In the latest quarter, TEM generated about $382M in revenue and pushed gross margin to roughly 73.5% at the financial-statement level, with separate commentary pointing to a 64% gross margin run-rate. For a fast-growing AI-in-healthcare platform, that kind of margin says the core data and software engine is starting to scale.

More important for active traders, TEM turned the corner on profitability. The company reported positive net income of roughly $5.6M and positive EPS around $0.03, helped by strong gross profit and tight control on operating costs relative to revenue growth. Free cash flow is still negative, at about -$18.6M, but the balance sheet shows roughly $816M in cash and short-term investments and a current ratio above 3. That gives Tempus AI room to keep funding R&D and acquisitions without urgent financing pressure.

More Breaking News

On the chart, TEM has ripped from the low $40s in late July to the high $60s on 2026/08/20. The stock closed near $67.31 after tagging an intraday high around $68.96, showing clear momentum and aggressive dip buying. Intraday 5‑minute candles reveal a strong trend day: a gap up near $61.71 at the open and a steady grind higher with shallow pullbacks. For short-term traders, this is classic “trend up, buy the dip” action as long as the high-$50s to low-$60s zone holds as support.

Why Traders Are Watching TEM Right Now

Tempus AI (TEM) is starting to look like the kind of story momentum traders hunt: strong fundamentals catching up with an already-hyped narrative, but with the stock still trading below earlier 2025 highs. Q2 revenue came in modestly above consensus, and management raised full-year guidance to roughly $1.6B. Add in that 64% gross margin and a move to positive net income, and TEM now has the financial profile of a real platform business, not just a high-burn AI science project.

The bigger-picture angle is TEM’s data moat. Tempus AI is described as sitting on hundreds of petabytes of clinical and genomic data, tied to tens of millions of patients and licensed out to pharma partners. For traders, that matters because true differentiated data is sticky. It makes it hard for rivals to copy the model, and it supports high-margin software and analytics revenue layered on top of testing and diagnostics.

Then there’s deal flow. Tempus AI is acquiring Personalis, a precision oncology MRD leader, for $16.25 per share. That folds more cancer-focused tools into the TEM ecosystem and deepens its reach in minimal residual disease testing, a high-value area in oncology. At the same time, a shareholder-rights firm is probing whether Tempus AI’s existing stake and strategic ties to Personalis led to an unfairly low price for PSNL shareholders. For TEM, that’s mostly headline risk — but headline risk can move a momentum name fast.

Put this together and you get the current tape: Tempus AI shares ripping off the lows, fueled by real earnings progress and a stronger narrative around AI models in healthcare, but still shadowed by questions about expectations, valuation, and governance. That’s exactly the kind of push-pull setup active traders like to stalk.

Conclusion

Tempus AI (TEM) now sits at an interesting crossroads for traders. On one side, you have a company that has raised full-year revenue guidance to around $1.6B, pushed gross margins into the 60%+ zone, and crossed into positive net income while continuing to fund big-ticket foundation-model R&D. The balance sheet shows ample liquidity, and the long-term story of a massive health-data platform — hundreds of petabytes, tens of millions of patients, pharma licensing — gives TEM a narrative wall of support.

On the other side, the stock is still trading well below its 2025 highs, and analysts have trimmed targets after earlier euphoria. The Personalis acquisition expands Tempus AI’s oncology footprint, but the parallel probe by a shareholder-rights firm adds legal and reputational overhang that nimble traders must respect. Add in negative free cash flow and rich valuation ratios, and there is zero room for execution mistakes.

For short-term players, the recent run from the low $40s to the high $60s is a reminder of how fast sentiment can flip once a name like Tempus AI pairs a strong story with cleaner numbers. As Tim Sykes likes to say, “Patterns repeat, but you have to study them and be ready — the market rewards preparation, not hope.” In a similar vein, disciplined day and swing traders often echo the mindset captured by As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.”. For TEM, that means tracking the chart, watching how the Personalis headlines evolve, and staying disciplined on entries and exits. This is educational and research-focused analysis only, but for active traders, Tempus AI is firmly on the watchlist.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!